Takeda Pharmaceutical Company Limited Stock Börse Stuttgart
Stocks
TKDA
US8740602052
Pharmaceuticals
OTC Markets Traded|
Real-time Estimate
Tradegate
15:40:02 28/08/2026 +03
|
5-day change | 1st Jan Change | ||
| 15.55 EUR | +0.97% |
|
-1.92% | +16.79% |
| 08-24 | FDA places clinical hold on Regenxbio's gene therapy for Hunter Syndrome | RE |
| 08-24 | Takeda's Orzeryful Approved in Japan as First Treatment Targeting Narcolepsy Type 1 | MT |
| Market Cap | 9,276B 58.22B 49.98B 46.79B 42.85B 80.71B 5,561B 80.94B 554B 217B 2,803B 219B 214B | P/E 2027 * |
46.6x | P/E 2028 * | 29.8x |
|---|---|---|---|---|---|
| Enterprise Value | 13,178B 82.72B 71.01B 66.48B 60.87B 115B 7,900B 115B 787B 308B 3,982B 311B 304B | EV / Sales 2027 * |
2.81x | EV / Sales 2028 * | 2.72x |
| Free-Float |
99.26% | Yield 2027 * |
3.52% | Yield 2028 * | 3.59% |
Last Transcript : Takeda Pharmaceutical Company Limited
| 1 day | +0.97% | ||
| 1 week | -1.92% | ||
| Current month | +3.38% | ||
| 1 month | +0.66% | ||
| 3 months | +12.50% | ||
| 6 months | -1.92% | ||
| Current year | +16.79% |
| 1 week | 15.3 |  | 15.6 |
| 1 month | 14.1 | | 15.6 |
| Current year | 12.7 | | 16.2 |
| 1 year | 11.6 | | 16.2 |
| 3 years | 11.6 | | 16.2 |
| 5 years | 11.6 | | 16.2 |
| 10 years | 11.6 | | 18.7 |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 56 | 01/01/2025 | |
Mikuno Furuta
DFI | Director of Finance/CFO | 48 | 01/04/2024 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/02/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Andrew Plump
BRD | Director/Board Member | 60 | 01/06/2015 |
Steven Gillis
BRD | Director/Board Member | 73 | 01/01/2019 |
Mikuno Furuta
BRD | Director/Board Member | 48 | 01/06/2024 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.97% | -1.92% | - | - | 58.22B | |
| -1.12% | -5.49% | +60.19% | +112.43% | 1,048B | |
| -1.57% | -0.60% | +50.33% | +59.86% | 640B | |
| -1.81% | -1.41% | +24.07% | +75.98% | 456B | |
| -0.76% | -3.73% | +38.54% | +39.53% | 362B | |
| -0.28% | -2.34% | +22.55% | +37.56% | 295B | |
| -0.31% | +0.20% | +1.70% | +11.75% | 255B | |
| -0.76% | +0.75% | +51.75% | +70.45% | 236B | |
| +0.97% | -0.83% | -16.85% | -53.85% | 204B | |
| +0.52% | +3.78% | +30.67% | +93.68% | 185B | |
| Average | +0.24% | -0.72% | +29.22% | +49.71% | 409.07B | |
| Weighted average by Cap. | +0.41% | -1.92% | +38.52% | +65.79% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 4,687B 29.42B 25.25B 23.64B 21.65B 40.78B 2,810B 40.9B 280B 109B 1,416B 110B 108B | 4,766B 29.92B 25.68B 24.04B 22.02B 41.47B 2,857B 41.59B 285B 111B 1,440B 112B 110B |
| Net income | 194B 1.22B 1.04B 978M 895M 1.69B 116B 1.69B 11.58B 4.53B 58.55B 4.57B 4.47B | 318B 1.99B 1.71B 1.6B 1.47B 2.76B 190B 2.77B 18.97B 7.41B 95.94B 7.48B 7.32B |
| Net Debt | 3,902B 24.49B 21.03B 19.69B 18.03B 33.96B 2,339B 34.05B 233B 91.12B 1,179B 91.97B 89.98B | 3,701B 23.23B 19.94B 18.67B 17.1B 32.21B 2,219B 32.3B 221B 86.43B 1,118B 87.23B 85.34B |
| Date | Price | Change |
|---|---|---|
| 28/08/26 | €15.30 | -0.65% |
| 27/08/26 | €15.40 | -0.65% |
| 26/08/26 | €15.50 | -0.64% |
| 25/08/26 | €15.60 | +0.65% |
| 24/08/26 | €15.50 | +0.65% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 4502 Stock
- TKDA Stock
Select your edition
All financial news and data tailored to specific country editions
